Wick Capital Partners LLC Invests $1.44 Million in Exelixis, Inc. $EXEL

Wick Capital Partners LLC acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 32,845 shares of the biotechnology company’s stock, valued at approximately $1,440,000.

A number of other institutional investors have also modified their holdings of the company. Anchor Investment Management LLC raised its holdings in Exelixis by 500.0% in the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 500 shares during the period. Motiv8 Investments LLC purchased a new stake in Exelixis during the fourth quarter worth approximately $26,000. Acumen Wealth Advisors LLC purchased a new stake in Exelixis during the fourth quarter worth approximately $29,000. Activest Wealth Management acquired a new stake in shares of Exelixis in the fourth quarter worth $32,000. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of Exelixis by 1,380.4% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 773 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Activity at Exelixis

In related news, EVP Dana Aftab sold 43,451 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total value of $2,187,757.85. Following the completion of the transaction, the executive vice president owned 594,741 shares of the company’s stock, valued at approximately $29,945,209.35. This represents a 6.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Patrick J. Haley sold 32,110 shares of Exelixis stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total value of $1,599,399.10. Following the sale, the executive vice president owned 357,638 shares in the company, valued at $17,813,948.78. This represents a 8.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 219,170 shares of company stock valued at $10,620,641. 2.60% of the stock is currently owned by insiders.

Exelixis Trading Down 1.0%

Shares of EXEL stock opened at $51.91 on Friday. The company has a market capitalization of $13.05 billion, a PE ratio of 17.25, a price-to-earnings-growth ratio of 1.51 and a beta of 0.41. The firm has a fifty day simple moving average of $48.66 and a 200-day simple moving average of $45.15. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $53.93.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The business had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. During the same period last year, the business earned $0.55 EPS. The business’s revenue was up 10.0% on a year-over-year basis. Equities research analysts predict that Exelixis, Inc. will post 3.16 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on EXEL. Morgan Stanley lifted their target price on shares of Exelixis from $49.00 to $50.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Weiss Ratings reiterated a “buy (b)” rating on shares of Exelixis in a report on Tuesday, May 19th. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Truist Financial upgraded Exelixis to a “strong-buy” rating in a research note on Monday, April 27th. Finally, Barclays upped their target price on Exelixis from $44.00 to $45.00 and gave the stock an “equal weight” rating in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $47.35.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.